Hutchison China Meditech Limited Exercise of Share Options (5202Q)
30 November 2016 - 7:51AM
UK Regulatory
TIDMHCM
RNS Number : 5202Q
Hutchison China Meditech Limited
30 November 2016
Exercise of Share Options by a Person Discharging Managerial
Responsibilities
London: Wednesday, November 30, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification
that Dr Weiguo Su, Executive Vice President and Chief Scientific
Officer (being a Person Discharging Managerial Responsibilities),
has exercised 25,535 share options (granted in 2007 and which are
soon due to expire in May 2017) over ordinary shares of US$1.00
each in Chi-Med (the "Ordinary Shares") at an exercise price of
GBP1.535 per share on November 25, 2016. Such Ordinary Shares will
be held in the form of American Depositary Shares ("ADSs") each
representing one half of one Ordinary Share.
Following the above exercise of options and subject to the
completion of allotment, the holding of Dr Su is 25,535 Ordinary
Shares, representing approximately 0.04% of the current issued
share capital of Chi-Med, which he intends to hold as a long term
investment. Additionally Dr Su holds a further 300,000 unexercised
options which would represent a further 0.49% of the issued share
capital of Chi-Med.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Dr Weiguo Su
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Vice President and Chief Scientific Officer
of Chi-Med
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary Shares of US$1.00 each in the form of ADSs
instrument each representing one half of one Ordinary
Identification code Share of US$1.00
DI ISIN: KYG4672N1016
ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Exercise of share options on November 25, 2016 at a
price of GBP1.535 per share. Such Ordinary
Shares will be held in the form of ADSs.
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP1.535 25,535
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information Aggregated volume: 25,535
- Aggregated volume Price information: GBP1.535
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2016-11-25
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Outside a trading venue
---- ------------------------------------------------------- -------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDBLBXQFFZFBV
(END) Dow Jones Newswires
November 30, 2016 02:51 ET (07:51 GMT)